GLP-1/glucagon dual receptor agonist ALT-801 is superior to semaglutide in improving NASH endpoints in a biopsy-confirmed DIO mouse model

被引：0
|
作者：
Nestor, John [1 ]
Rigbolt, Kristoffer [2 ]
Feigh, Michael [2 ]
Parkes, David [3 ]
Harris, M. Scott [1 ]
机构：
[1] Altimmune Inc, Gaithersburg, MD USA
[2] Gubra, Horsholm, Denmark
[3] DGP Sci, Del Mar, CA USA
来源：
JOURNAL OF HEPATOLOGY | 2020年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
FRI117
引用
收藏
页码：S456 / S456
页数：1
相关论文
共 45 条
  • [1] Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis
    John J. Nestor
    David Parkes
    Michael Feigh
    John J. Suschak
    M. Scott Harris
    Scientific Reports, 12
  • [2] Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis
    Nestor, John J.
    Parkes, David
    Feigh, Michael
    Suschak, John
    Harris, M. Scott
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [3] Effect of Pemvidutide (ALT-801), a Novel GLP-1/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators
    Plutzky, Jorge
    Harris, M. Scott S.
    Alonso, Cristina
    Suschak, John
    Noor, Mustafa
    Ortiz, Pablo
    Georges, Bertrand
    Rader, Daniel J.
    Roberts, Scot S.
    Browne, Sarah K.
    CIRCULATION, 2022, 146
  • [4] Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/ glucagon agonism in NASH patients
    Monfeuga, Thomas
    Norlin, Jenny
    Bugge, Anne
    Gaalsgaard, Elisabeth D.
    Prada-Medina, Cesar A.
    Latta, Markus
    Veidal, Sanne S.
    Petersen, Pia S.
    Feigh, Michael
    Holst, Dorte
    MOLECULAR METABOLISM, 2024, 79
  • [5] Superior Efficacy of a Dual GLP-1/Glucagon Receptor Agonist in Reversing Steatosis and Improving Indices of Nonalcoholic Steatohepatitis (NASH) Compared with GLP-1 Receptor and FXR Agonists in a Mouse Model of NASH
    Trevaskis, James L.
    Jouihan, Hani
    Bednarek, Maria
    Veidal, Sanne S.
    Feigh, Michael
    Knudsen, Sanne M.
    Jelsing, Jacob
    Vrang, Niels
    Konkar, Anish
    Grimsby, Joseph
    Rondinone, Cristina
    Jermutus, Lutz
    DIABETES, 2016, 65 : A19 - A19
  • [6] Coadministration of a GLP-1/Glucagon Receptor Agonist with an FXR Agonist and ACC Inhibitor Reverses Nonalcoholic Steatohepatitis (NASH) in Diet-Induced and Biopsy-Confirmed Mice
    Trevaskis, James L.
    Norlin, Jenny
    Miranda, Diego A.
    Bates, Jamie G.
    Zois, Nora E.
    Veidal, Sanne
    Feigh, Michael
    Latta, Markus
    DIABETES, 2020, 69
  • [7] Triple Combination Therapy of GLP-1 Receptor Agonist Semaglutide with an FXR Agonist and AC Inhibitor Reverses Nonalcoholic Steatohepatitis (NASH) in Diet-Induced and Biopsy-Confirmed Mice
    Norlin, Jenny
    Miranda, Diego A.
    Bates, Jamie G.
    Zois, Nora E.
    Veidal, Sanne
    Feigh, Michael
    Trevaskis, James L.
    Latta, Markus
    DIABETES, 2020, 69
  • [8] Exploring the therapeutic potential of Glucagon/GLP-1 dual agonist ZP2929 in a mouse model of diet induced and biopsy-confirmed non-alcoholic steatohepatitis
    Skarbaliene, J.
    Madsen, A. N.
    Mouritzen, U.
    Bak, H. H.
    Just, R.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S102 - S102
  • [9] MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, Dramatically Reduces Hepatic Collagen in a Mouse Model of NASH
    Beaton, Michelle
    Guionaud, Silvia
    Conway, James P.
    Grimsby, Joe
    Rhodes, Christopher J.
    Jermutus, Lutz
    Trevaskis, James
    DIABETES, 2018, 67
  • [10] MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, Dramatically Reduces Hepatic Collagen in a Mouse Model of NASH
    Beaton, Michelle
    Guionaud, Silvia
    Conway, James P.
    Grimsby, Joe
    Rhodes, Christopher J.
    Jermutus, Lutz
    Trevaskis, James
    DIABETES, 2019, 68
12345